Chairman Bob Gower Discloses 6.1% Stake, Support Agreement for Cy Biopharma Merger
ENSC sits 61% above its 52-week low of $0.23 on light trading volume (0.2× avg).
Summary
Chairman Bob Gower disclosed a 6.1% stake and a Support Agreement to vote for the Cy Biopharma merger, including a potential reverse split. The filing also reveals a note conversion and warrant issuance.
Key Events · Ownership and Investor Activity · ENSC
-
Chairman Discloses 6.1% Stake
Bob Gower beneficially owns 1,206,576 shares (6.1% of 19,456,794 outstanding), including 916,740 shares held directly, 2,013 options, and 287,823 warrants.
-
Support Agreement for Merger
Gower signed a Support Agreement on August 5, 2026, obligating him to vote for the Cy Biopharma merger proposals, including Series C conversion and a potential reverse stock split to maintain Nasdaq listing.
-
Note Conversion and Warrant
On April 23, 2026, $246,169 of convertible notes were converted into 508,614 shares and a warrant for 254,307 shares at $0.484 exercise price.
-
Open-Market Purchase
On August 7, 2026, Gower bought 400,000 shares at $0.495 per share for $198,000, triggering the 13D filing.
Analysis · ENSC · Life Sciences
Chairman Bob Gower's amended 13D reveals a 6.1% beneficial ownership stake (1,206,576 shares) and a binding Support Agreement to vote for the Cy Biopharma merger proposals, including a potential reverse stock split and Series C conversion. The filing also discloses a $246,169 note conversion into 508,614 shares and a warrant for 254,307 shares at $0.484. This aligns Gower's interests with the merger and signals insider commitment, but the stake is modest relative to the company's market cap and the merger was already announced.
At the time of this filing, ENSC was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.23 to $2.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.